{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:22:00Z","timestamp":1791105720656,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000864","name":"The Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.neuropharm.2013.06.005","type":"journal-article","created":{"date-parts":[[2013,6,14]],"date-time":"2013-06-14T08:25:24Z","timestamp":1371198324000},"page":"337-347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque"],"prefix":"10.1016","volume":"73","author":[{"given":"Tom H.","family":"Johnston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Huot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan H.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Koprich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendall T.","family":"Szeliga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Graef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon R.","family":"Letchworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen G.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Brotchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2013.06.005_bib1","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/mds.870130507","article-title":"Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys","volume":"13","author":"Blanchet","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1124\/jpet.108.140897","article-title":"Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (l-DOPA)-induced dyskinesias in a rat model of Parkinson's disease","volume":"327","author":"Bordia","year":"2008","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib3","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1124\/jpet.109.162396","article-title":"Nicotinic receptor-mediated reduction in l-DOPA-induced dyskinesias may occur via desensitization","volume":"333","author":"Bordia","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib4","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.drudis.2010.08.014","article-title":"l-DOPA-induced dyskinesia in Parkinson's disease: a drug discovery perspective","volume":"15","author":"Buck","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.neuropharm.2013.06.005_bib5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/mds.20279","article-title":"Impact of the motor complications of Parkinson's disease on the quality of life","volume":"20","author":"Chapuis","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib6","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/mds.21475","article-title":"Levodopa-induced dyskinesias","volume":"22","author":"Fabbrini","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/mds.1280","article-title":"Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia","volume":"17","author":"Fox","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib8","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/mds.20464","article-title":"Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004","volume":"20","author":"Goetz","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/mds.20828","article-title":"Histamine H3 receptor agonists reduce l-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease","volume":"21","author":"Gomez-Ramirez","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib10","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1523\/JNEUROSCI.5095-09.2010","article-title":"Nicotinic acetylcholine receptors in the mesolimbic pathway: primary role of ventral tegmental area alpha6beta2* receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement","volume":"30","author":"Gotti","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib11","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1021\/jm970377o","article-title":"Neuronal nicotinic acetylcholine receptors as targets for drug discovery","volume":"40","author":"Holladay","year":"1997","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib12","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.neuropharm.2010.12.032","article-title":"Nicotinic receptor agonists decrease l-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats","volume":"60","author":"Huang","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.06.005_bib13","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1124\/jpet.111.182949","article-title":"Nicotine reduces l-DOPA-induced dyskinesias by acting at beta2* nicotinic receptors","volume":"338","author":"Huang","year":"2011","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib14","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.neuropharm.2012.06.012","article-title":"l-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease","volume":"63","author":"Huot","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.06.005_bib15","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/ejn.12093","article-title":"Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque","volume":"37","author":"Huot","year":"2013","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib16","series-title":"Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1\/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinson's Disease","author":"Inc","year":"2010"},{"key":"10.1016\/j.neuropharm.2013.06.005_bib17","series-title":"Guide for the Care and Use of Laboratory Animals","author":"Institute of Laboratory Animal Resources (U.S.). Committee on Care and Use of Laboratory Animals, N","year":"1996"},{"key":"10.1016\/j.neuropharm.2013.06.005_bib18","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1124\/jpet.110.166629","article-title":"Reduction of l-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease","volume":"333","author":"Johnston","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib19","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1002\/mds.23172","article-title":"The alpha adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates","volume":"25","author":"Johnston","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib20","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1124\/mol.58.2.312","article-title":"alpha-bungarotoxin-sensitive nicotinic receptors indirectly modulate [(3)H]dopamine release in rat striatal slices via glutamate release","volume":"58","author":"Kaiser","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib21","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.bcp.2011.06.022","article-title":"Progress and challenges in the study of alpha6-containing nicotinic acetylcholine receptors","volume":"82","author":"Letchworth","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1212\/WNL.0b013e31825f0451","article-title":"Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)","volume":"79","author":"Lewitt","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2013.06.005_bib23","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s11940-011-0122-0","article-title":"Treatment of generalized dystonia","volume":"13","author":"Lubarr","year":"2011","journal-title":"Curr. Treat Options Neurol."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nrd3430","article-title":"Priorities in Parkinson's disease research","volume":"10","author":"Meissner","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib25","first-page":"S591","article-title":"The paddy-2 study: the evaluation of sarizotan for treatment-associated dyskinesia in PD patients","volume":"21","author":"Muller","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/mds.870020107","article-title":"Anticholinergic-induced chorea in the treatment of focal dystonia","volume":"2","author":"Nomoto","year":"1987","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib27","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1212\/01.wnl.0000215250.82576.87","article-title":"Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"66","author":"Pahwa","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2013.06.005_bib28","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ana.410390505","article-title":"Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys","volume":"39","author":"Papa","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib29","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1124\/mol.110.067561","article-title":"alpha6beta2* and alpha4beta2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's disease","volume":"78","author":"Perez","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib30","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1212\/WNL.0b013e31819908ce","article-title":"Treatments for Parkinson disease\u2013past achievements and current clinical needs","volume":"72","author":"Poewe","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2013.06.005_bib31","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1124\/pr.110.003269","article-title":"alpha6beta2* and alpha4beta2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease","volume":"63","author":"Quik","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib32","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/mol.104.006015","article-title":"Subunit composition of nicotinic receptors in monkey striatum: effect of treatments with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine or l-DOPA","volume":"67","author":"Quik","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib33","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ana.21203","article-title":"Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys","volume":"62","author":"Quik","year":"2007","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib34","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/mds.21900","article-title":"Nicotine and Parkinson's disease: implications for therapy","volume":"23","author":"Quik","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib35","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.neuropharm.2012.04.029","article-title":"Role for alpha6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice","volume":"63","author":"Quik","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.06.005_bib36","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.neuropharm.2013.03.038","article-title":"alpha4beta2 nicotinic receptors play a role in the nAChR-mediated decline in l-dopa-induced dyskinesias in parkinsonian rats","volume":"71","author":"Quik","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.06.005_bib37","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.nbd.2012.09.006","article-title":"Nicotine-mediated improvement in l-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function","volume":"50","author":"Quik","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib38","first-page":"S492","article-title":"A\u00a0large phase III study to evaluate the safety and efficacy of sarizotan in the treatment of l-dopa-induced dyskinesia associated with Parkinson\u2019s disease: the Paddy-1 study","volume":"21","author":"Rascol","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ana.410320118","article-title":"Dystonia induced by combined treatment with l-dopa and MK-801 in parkinsonian monkeys","volume":"32","author":"Rupniak","year":"1992","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib40","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1124\/mol.65.6.1526","article-title":"Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice","volume":"65","author":"Salminen","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib41","first-page":"141","article-title":"Duration of amantadine benefit on dyskinesia of severe Parkinson's disease","volume":"75","author":"Thomas","year":"2004","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.neuropharm.2013.06.005_bib42","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","article-title":"Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease","volume":"50","author":"Verhagen Metman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2013.06.005_bib43","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1124\/jpet.108.144097","article-title":"Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques","volume":"328","author":"Visanji","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Ther."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813002657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813002657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T11:15:42Z","timestamp":1563189342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390813002657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":43,"alternative-id":["S0028390813002657"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.06.005","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}